Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$45.72 ▼ -0.04
(-0.09%)
MKT CAP: $1.36B • VOL: 482.2K
52W L $31 52W H $54
CNMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.37B | $1.31B | $1.24B |
| YoY Revenue Growth % | +5.2% | +5.0% | — |
| Gross Profit | $750.5M | $733.0M | — |
| Gross Margin % | 54.6% | 56.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $102.6M | $200.3M | $120.6M |
| Operating Margin % | 7.5% | 15.3% | 9.7% |
| Net Income (GAAP) | $47.1M | $132.4M | $64.5M |
| EBITDA (Normalized) | $118.5M | $210.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $170.7M | $167.0M | $125.3M |
| Capital Expenditures (CapEx) | $19.8M | $13.1M | — |
| Free Cash Flow (FCF) | $150.9M | $153.9M | $125.3M |
| FCF Margin % | 11.0% | 11.8% | 10.1% |
| Return on Invested Capital (ROIC %) | 7.8% | 16.4% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.03B | $962.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CNMD.